✦ LIBER ✦

9084 POSTER A Global Phase 2 Study Including Efficacy, Safety and Patient-reported Outcomes (PROs) With Crizotinib in Patients (Pts) With ALK-positive Non-small Cell Lung Cancer (NSCLC)

✍ Scribed by Kim, D.W.; Blackhall, F.; Soria, J.C.; Solomon, B.; Camidge, D.R.; Riely, G.J.; Bottomley, A.; Tassell, V.; Polli, A.; Shaw, A.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Activity and safety of crizotinib in pat

✍ D Ross Camidge; Yung-Jue Bang; Eunice L Kwak; A John Iafrate; Marileila Varella- 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 310 KB

6551 POSTER Efficacy and safety of singl

✍ von Pawel, J.; Larson, T.; Ou, S.I.; Limentani, S.A.; Sandler, A.B.; Vokes, E.E. 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 61 KB

A randomised phase II study of gemcitabi

✍ U. Gatzemeier; G. Groth; V. Hirsh; C. Butts; N. Van Zandwijk; F. Shepherd; R. Ro 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 160 KB

A Phase 2 Study of Erlotinib (ERL) and H

✍ Werner-Wasik, M.; Pequignot, E.; Campling, B.; Shi, W.; Bhatia, A.; Wang, Z.; Sh 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 42 KB

Safety and activity of alectinib against

✍ Gadgeel, Shirish M; Gandhi, Leena; Riely, Gregory J; Chiappori, Alberto A; West, 📂 Article 📅 2014 🏛 The Lancet 🌐 English ⚖ 385 KB

68O EFFICACY, SAFETY AND TOLERABILITY RE

✍ Douillard, J.; Ostoros, G.; Cobo, M.; Ciuleanu, T.; McCormack, R.; Webster, A.; 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 45 KB